Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company is headquartered in Estero, Florida. The company went IPO on 2022-02-18. DCSC maintains a powertrain agnostic product portfolio that includes mechatronic actuators, human machine interfaces, industrial cables, and cable control systems backed by over 310 patents. The firm operates 11 manufacturing facilities globally and serves as a tier one automotive supplier to major OEMs and other industrial firms. The firm also engages in the business of developing and marketing disruptive technology for novel sublingual delivery mechanisms initially for known drugs and supplements, such as aspirin and caffeine products.
P/E (price / listing EPS) Forward revenue growth (NTM) 
